Cardior Pharmaceuticals, a Hannover, Germany-based biotech company advancing non-coding RNA-based therapeutics in heart failure, completed a €15m Series A financing.
The round was led by LSP (Life Sciences Partners), Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS), BioMedPartners (with its new BioMedInvest III Fund) and High-Tech Gründerfonds (HTGF).
The company will use the funds to continue to advance its therapeutics.
Led by Dr. Claudia Ulbrich, Chief Executive Officer, and Prof. Thomas Thum, Chief Scientific Officer, Cardior is a spin-off from Hannover Medical School (MHH) that develops proprietary RNA technology to predict and treat heart failure.
The molecular targets are non-coding RNAs linked to heart failure development that simultaneously control cardiac growth and calcium handling/contractility of cardiomyocytes. The targeting of certain specific non-coding RNAs reverses maladaptive cardiac remodeling and restores normal cardiac function.